JNJ

227.72

+0.42%↑

UNH

388.18

-1.39%↓

TMO

439.13

+0.22%↑

ISRG

433.1

+2.84%↑

ABT

86.76

+2.76%↑

JNJ

227.72

+0.42%↑

UNH

388.18

-1.39%↓

TMO

439.13

+0.22%↑

ISRG

433.1

+2.84%↑

ABT

86.76

+2.76%↑

JNJ

227.72

+0.42%↑

UNH

388.18

-1.39%↓

TMO

439.13

+0.22%↑

ISRG

433.1

+2.84%↑

ABT

86.76

+2.76%↑

JNJ

227.72

+0.42%↑

UNH

388.18

-1.39%↓

TMO

439.13

+0.22%↑

ISRG

433.1

+2.84%↑

ABT

86.76

+2.76%↑

JNJ

227.72

+0.42%↑

UNH

388.18

-1.39%↓

TMO

439.13

+0.22%↑

ISRG

433.1

+2.84%↑

ABT

86.76

+2.76%↑

Home・Akcijų sąrašas・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

14.49 0.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.49

Max

14.49

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-16M 1.7M
Pardavimai	16M 185M
Pelno marža	0.912
Darbuotojai	511
EBITDA	-31M 16M

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	61M 4.5B
Ankstesnė atidarymo kaina	14.28
Ankstesnė uždarymo kaina	14.49

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

5.925 / 7.38 Palaikymas ir pasipriešinimas

Amicus Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-30 23:08; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 23:07; UTC

Uždarbis

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:20; UTC

Uždarbis

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

2026-04-30 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 23:47; UTC

Rinkos pokalbiai

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

2026-04-30 23:27; UTC

Rinkos pokalbiai

Liontown Lithium Recovery Expected to Improve -- Market Talk

2026-04-30 23:22; UTC

Uždarbis

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

2026-04-30 23:20; UTC

Rinkos pokalbiai

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

2026-04-30 22:52; UTC

Uždarbis

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

2026-04-30 22:33; UTC

Uždarbis

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

2026-04-30 22:32; UTC

Uždarbis

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

2026-04-30 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

2026-04-30 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-30 22:11; UTC

Rinkos pokalbiai

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

2026-04-30 22:05; UTC

Uždarbis

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

2026-04-30 21:57; UTC

Uždarbis

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

2026-04-30 21:56; UTC

Uždarbis

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

2026-04-30 21:55; UTC

Uždarbis

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

2026-04-30 21:54; UTC

Uždarbis

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

2026-04-30 21:53; UTC

Uždarbis

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

2026-04-30 21:49; UTC

Uždarbis

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Akcijų palyginimas

Kainos pokytis

Amicus Therapeutics Inc Prognozė

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Amicus Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

5.925 / 7.38Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Apie bendrovę Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.